AOA Dx is developing GlycoLocate™, a multi-omics platform that utilizes tumor marker gangliosides for early-stage cancer detection, specifically through the AKRIVIS GD™ liquid biopsy test for ovarian cancer. This technology offers high sensitivity and specificity, addressing the critical need for effective early diagnosis in women's health.
Funding
$24.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+8Founders
Product
Problem
Early cancer detection, particularly in women's health, faces challenges due to the limitations of current diagnostic methods. Existing technologies often lack the sensitivity and specificity needed to identify cancers at their earliest stages, leading to delayed diagnoses and poorer patient outcomes. The need for non-invasive, accurate, and cost-effective screening tools remains a critical unmet need.
Solution
AOA Dx is developing GlycoLocate™, a multi-omics platform designed for the early detection of cancer, with an initial focus on women's health. The platform leverages tumor marker gangliosides and other complementary biomarkers, analyzed through data science and AI, to provide insights into early-stage cancers. Their lead product, AKRIVIS GD™, is a liquid biopsy test for ovarian cancer that utilizes these biomarkers to achieve high sensitivity and specificity. By harnessing the power of lipidomics, AOA Dx aims to improve early detection rates, enabling timely intervention and improved patient outcomes.
Target Audience
The primary target audience includes healthcare providers specializing in women's health, oncologists, and diagnostic laboratories seeking advanced tools for early cancer detection.
Features
- Multi-omics platform analyzing tumor marker gangliosides and other biomarkers
- AKRIVIS GD™ liquid biopsy test for early-stage ovarian cancer detection
- AI-driven data analysis for enhanced insights and accuracy
- Non-invasive blood test methodology
- High sensitivity and specificity for early cancer detection
- Utilizes liquid chromatography-mass spectrometry (LC-MS) technology